PhaseBio Pharmaceuticals, Inc. (2K4.F)

0.0690 0.0000 (0.00%) At close: 10:16AM CEST

PhaseBio Pharmaceuticals, Inc.

1 Great Valley Parkway
Suite 30
Malvern, PA 19355
United States
610 981 6500
https://phasebio.com

Sector(s): 
Industry: 
Full Time Employees: 60

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Jonathan P. Mow MBA	President, CEO & Director	834.78k	N/A	1965
Mr. Lawrence R. Perkins	Chief Restructuring Officer & Principal Financial Officer	N/A	N/A	1977
Ms. Susan Elizabeth Arnold Ph.D.	Senior Vice President of Technical Operations	N/A	N/A	1975
Mr. Kristopher L. Hanson	SVP, General Counsel & Corporate Secretary	N/A	N/A	1972
Mr. Glen G. Burkhardt	Senior Vice President of Human Resources	N/A	N/A	1959
Mr. Jonathan J. Birchall	Chief Commercial Officer	N/A	N/A	1969

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Corporate Governance

PhaseBio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.